Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
28 February 2019 |
Main ID: |
EUCTR2008-000972-25-GB |
Date of registration:
|
08/12/2010 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study to compare efficacy and safety of masitinib at 6 mg/kg/day to
placebo in treatment of patients with Systemic mastocytosis with severe handicap
|
Scientific title:
|
A 24-week with possible extension, prospective, multicentre, randomized,
double blind, placebo-controlled, 2-parallel group with a randomization
1:1, Phase 3 study to compare efficacy and safety of masitinib at 6
mg/kg/day to placebo in treatment of patients with Smouldering Systemic,
Indolent Systemic or Cutaneous Mastocytosis with handicap.
|
Date of first enrolment:
|
24/03/2011 |
Target sample size:
|
150 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-000972-25 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Bulgaria
|
Czech Republic
|
France
|
Germany
|
Greece
|
Hungary
|
India
|
Italy
|
Latvia
|
Mexico
|
Poland
|
Romania
|
Russian Federation
|
Slovakia
|
Spain
|
Ukraine
|
United Kingdom
|
United States
| | | |
Contacts
|
Name:
|
Clinical Project Manager
|
Address:
|
3 avenue Georges V
75008
PARIS
France |
Telephone:
|
33147209783 |
Email:
|
igor.antonshchuk@ab-science.com |
Affiliation:
|
AB Science |
|
Name:
|
Clinical Project Manager
|
Address:
|
3 avenue Georges V
75008
PARIS
France |
Telephone:
|
33147209783 |
Email:
|
igor.antonshchuk@ab-science.com |
Affiliation:
|
AB Science |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Patient with one of the following documented mastocytosis as per WHO classification:
Smouldering Systemic Mastocytosis
Indolent Systemic Mastocytosis
2. Patient with documented mastocytosis and evaluable disease based upon histological criteria: typical
infiltrates of mast cells in a multifocal or diffuse pattern in skin and/or bone marrow biopsy
3. Patient with documented treatment failure of his/her handicap(s) with at least one of the following therapy
used at optimized dose (refer to table 2):
Anti H1
Anti H2
Proton pump inhibitor
Osteoclast inhibitor
Cromoglycate Sodium
Antileukotriene
4. Handicapped status defined as at least two of the following handicaps, including at least one among pruritus,
flushes, depression and fatigue:
Pruritus score = 9
Number of flushes per week = 8
Hamilton rating scale for depression(HAMD-17) score = 19
Number of stools per day = 4
Number of micturition per day = 8
Fatigue Impact Scale total score (asthenia) = 75 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 130 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20
Exclusion criteria: 1. Patient with one of the following mastocytosis:
Cutaneous Mastocytosis
Not documented Smouldering Systemic Mastocytosis or Indolent Systemic Mastocytosis
Systemic Mastocytosis with an Associated clonal Hematologic Non Mast cell lineage Disease (SMAHNMD)
Mast cell leukaemia (MCL)
Aggressive systemic mastocytosis (ASM)
2. Previous treatment with any Tyrosine Kinase Inhibitor
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Smouldering Systemic or Indolent Systemic Mastocytosis with handicaps
MedDRA version: 17.0
Level: PT
Classification code 10026891
Term: Mastocytosis
System Organ Class: 10005329 - Blood and lymphatic system disorders
|
Therapeutic area: Diseases [C] - Cancer [C04]
|
Intervention(s)
|
Product Name: AB1010 Tablets Product Code: AB1010 Tablets Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- INN or Proposed INN: Masitinib mesylate CAS Number: 790-299-79-5 Current Sponsor code: AB1010 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Secondary Objective: - Cumulative response on pruritus among patients with the handicap at Baseline - Cumulative response on OPA score among patients with “severe” or “intolerable” handicap at Baseline - Quality of Life (QoL) : QLQ-C30 global score, functional scores and symptom scores at each visit - AFIRMM questionnaire : • global score • for each of the 52 items : cumulative response among patients with “severe” or “intolerable” handicap at Baseline - Cumulative response on micturitions among patients with the handicap at Baseline - Cumulative response on stools among patients with the handicap at Baseline - Urticaria Pigmentosa (UP) evaluation at week 12, 24 and then every 12 weeks - Mastocytosis symptoms rebound effect evaluation from 1 month after study/treatment discontinuation. Safety profile of masitinib: Occurrence of Adverse Events, vital signs, EKG, Chest X-Ray, cardiac ultrasonography and biological parameters.
|
Main Objective: The objective is to compare the safety and efficacy of masitinib to placebo in patients with documented Smouldering or Indolent Systemic mastocytosis with severe handicap. Primary endpoint: - Cumulative response by patient*handicap
|
Primary end point(s): Primary variable: Cumulative response by patient*handicap For all the patients, the response at each study visit (5 visits from week 8 to week 24) will be calculated on each handicap present at Baseline (among pruritus, flushes, Hamilton and FIS) as defined above. If data are not available for assessment at a visit because a patient left the study prematurely or had no measurement at the visit, missing data will be considered as failure (missing = failure as primary analysis). Week 4 is not considered for the calculation of this response as : -All patients take anti-histamines between Baseline and week 4 even if they didn’t take such treatment before study entry -Based on phase II studies, first month of treatment is under efficient So, from 5 to 20 responses will be calculated by patient : 5 if the patients presents only 1 handicap at Baseline corresponding to the 5 visits and 20 if the patients presents the 4 handicaps at Baseline corresponding to the 4 handicaps * the 5 visits. Sensitivity analysis: same analysis but with Last Observation Carried Forward (LOCF) then with Observed Cases (data remain missing) instead of missing = failure if data are not available for assessment at a visit because a patient left the study prematurely or had no measurement at the visit.
|
Timepoint(s) of evaluation of this end point: Overall duration of treatment
|
Secondary Outcome(s)
|
Secondary end point(s): -Cumulative response on pruritus among patients with the handicap at Baseline
-Cumulative response on OPA score among patients with “severe” or “intolerable” handicap at Baseline
-Quality of Life (QoL) : QLQ-C30 global score, functional scores and symptom. scores at each visit
-AFIRMM questionnaire :
•global score
•for each of the 52 items : cumulative response among patients with “severe” or “intolerable” handicap at Baseline
-Cumulative response on micturitions among patients with the handicap at Baseline
-Cumulative response on stools among patients with the handicap at Baseline
-Urticaria Pigmentosa (UP) evaluation at week 12, 24 and then every 12 weeks
- Mastocytosis symptoms rebound evaluation
Percentage of patients who experiencing a rebound effect on at least one symptom after discontinuation. Mean number of symptoms showing a rebound per discontinued patients. Percentage of patients who experiencing a rebound effect per symptom. Mean time of the occurrence of the rebound effect. Symptom severity will be described. Patient overall wellbeing from treatment period will be also described.
|
Secondary ID(s)
|
2008-000972-25-FR
|
AB06006
|
Source(s) of Monetary Support
|
AB Science
|
Ethics review
|
Status: Approved
Approval date:
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|